Skip to main content

Advertisement

SpringerLink
Log in

Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

To compare the outcome of allogeneic stem cell transplantation for myeloid malignancies in breast cancer survivors to a contemporaneous control group.

Methods

Medical records of all patients with a history of breast cancer who received allogeneic stem cell transplants at a single, tertiary referral Comprehensive Cancer Center between 2002 and 2019 were reviewed. Transplant outcomes were compared to 289 control patients without a history of breast cancer from the same time period. Main outcomes included survival, disease-free survival, non-relapse mortality, relapse or progression of hematologic malignancy, and incidence of recurrent breast cancer after hematopoietic cell transplantation. Comparisons between women with a history of breast cancer and controls utilized propensity score weighting to balance patient characteristics.

Results

Forty women, ages 30–74 years, with a history of breast cancer received an allogeneic hematopoietic cell transplant for a hematologic malignancy between December 2002 and February 2019. Twelve of the 40 patients are alive with a median survival of 7.4 years (range, 1.9–16.8 years). None of the patients had evidence of recurrent breast cancer prior to death or date of last contact. In multivariable Cox models, all transplant outcomes were similar between the patients and the control group with hematopoietic cell transplant comorbidity score as the most important confounding factor for adjustment in these models.

Conclusion

A history of treated breast cancer should not exclude patients from consideration for allogeneic hematopoietic cell transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Enquiries about data availability should be directed to the authors.

References

  1. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438–451

    Article  Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975–2017. In.: National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.

  3. Lavey RS, Eby NL, Prosnitz LR (1990) Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer 66(5):874–881

    Article  CAS  Google Scholar 

  4. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326(26):1745–1751

    Article  CAS  Google Scholar 

  5. Obedian E, Fischer DB, Haffty BG (2000) Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18(12):2406–2412

    Article  CAS  Google Scholar 

  6. Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J, Powles R, Ashley S, Kuan A, Powles T (2000) Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 83(1):91–94

    Article  CAS  Google Scholar 

  7. Smith RE, Bryant J, DeCillis A, Anderson S (2003) National Surgical Adjuvant B, Bowel Project E: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21(7):1195–1204

    Article  CAS  Google Scholar 

  8. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R et al (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23(18):4179–4191

    Article  CAS  Google Scholar 

  9. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH (2007) Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25(25):3871–3876

    Article  Google Scholar 

  10. Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A (2008) Institut curie breast cancer study G: second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98(5):870–874

    Article  CAS  Google Scholar 

  11. Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A (2007) Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys 68(2):359–363

    Article  Google Scholar 

  12. Karp JEBA, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, et al (2012) Myelodysplastic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. In: Paper presented at the American Association of Cancer Research. https://cancerres.aacrjournals.org/content/72/24_Supplement/S3-5

  13. Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK (2017) Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast 35:122–129

    Article  Google Scholar 

  14. Bazire L, De Rycke Y, Asselain B, Fourquet A, Kirova YM (2017) Risks of second malignancies after breast cancer treatment: long-term results. Cancer Radiother 21(1):10–15

    Article  CAS  Google Scholar 

  15. Mayer EL (2013) Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol 2013:9–14

    Article  Google Scholar 

  16. Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, Woodle ES (2009) De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 87(9):1347–1359

    Article  Google Scholar 

  17. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE (1978) The analysis of failure times in the presence of competing risks. Biometrics 34(4):541–554

    Article  CAS  Google Scholar 

  18. Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11(5):550–560

    Article  CAS  Google Scholar 

  19. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846

    Article  Google Scholar 

  20. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

    Article  Google Scholar 

  21. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628–1633

    Article  Google Scholar 

  22. Why, When and Where to Report Conditioning Drugs [https://www.cibmtr.org/Meetings/Materials/CRPDMC/Pages/2015Index.aspx ]. Accessed 11 Feb 2021

  23. AlBugami M, Kiberd B (2014) Malignancies: pre and post transplantation strategies. Transplant Rev (Orlando) 28(2):76–83

    Article  Google Scholar 

  24. Rossi AP, Klein CL (2019) Posttransplant Malignancy. Surg Clin North Am 99(1):49–64

    Article  Google Scholar 

  25. Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI et al (2012) New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) 26(4):261–279

    Article  Google Scholar 

  26. Wong G, Au E, Badve SV, Lim WH (2017) Breast cancer and transplantation. Am J Transplant 17(9):2243–2253

    Article  CAS  Google Scholar 

  27. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR (2007) Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 7(9):2140–2151

    Article  CAS  Google Scholar 

  28. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE (2006) Cancer incidence before and after kidney transplantation. JAMA 296(23):2823–2831

    Article  CAS  Google Scholar 

  29. Swerdlow SCE, Harris NL et al (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised, 4th edn. International Agency for Research on Cancer IARC, Lyon

    Google Scholar 

  30. Lazarus G, Audrey J, Iskandar AWB (2019) Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. Oncol Rev 13(2):425

    Article  CAS  Google Scholar 

  31. Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M et al (2020) PELICAN-IPC 2015–016/Oncodistinct-003: a prospective, multicenter, open-label, randomized, non-comparative, phase ii study of pembrolizumab in combination with neo adjuvant EC-paclitaxel regimen in HER2-negative inflammatory breast cancer. Front Oncol 10:575978

    Article  Google Scholar 

  32. Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821

    Article  CAS  Google Scholar 

  33. Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P et al (2021) Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol 39(22):2443–2451

    Article  CAS  Google Scholar 

  34. Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94–99

    Article  CAS  Google Scholar 

  35. Soiffer RJ, Davids MS, Chen YB (2018) Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood 131(10):1073–1080

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge Chris Davis for his help in accessing transplantation data for this patient population.

Funding

This work was supported by NIH/NCI, P30 CA015704, Wendy Leisenring, P30 CA015704, Hannah Linden.

Author information

Authors and Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, D5-280, PO Box 19024, Seattle, WA, 98109-1024, USA

    Kristine Doney & Wendy Leisenring

  2. University of Washington Medical Center, Seattle, WA, USA

    Kristine Doney, Wendy Leisenring & Hannah Linden

  3. Seattle Cancer Care Alliance, Seattle, WA, USA

    Hannah Linden

Authors
  1. Kristine Doney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wendy Leisenring
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hannah Linden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristine Doney.

Ethics declarations

Conflict of interest

The authors have not disclosed any competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOC 34 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doney, K., Leisenring, W. & Linden, H. Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer. Breast Cancer Res Treat 194, 507–516 (2022). https://doi.org/10.1007/s10549-022-06658-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-022-06658-5

Keywords

Search

Navigation